Clinical Evaluation of [68Ga]Ga-XT771 PET for Diagnosis in Patients With Glioblastoma and Clear Cell Renal Cell Carcinoma

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT07067905

Enrollment

Registered

2025-07-16

Start date

2025-06-27

Completion date

2026-06-01

Last updated

2025-07-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Clear Cell Renal Cell Carcinoma and Glioblastoma

Keywords

clear cell renal cell carcinoma, glioblastoma, CAIX, CAXII, XT771

Brief summary

A prospective, open-label, phase 1 study. This clinical trial aims to evaluate the diagnostic value of 68Ga-XT771, a CAIX/CAXII protein-specific probe, in PET/CT imaging for patients with clear cell renal cell carcinoma and glioblastoma. Safety, tolerability, and biodistribution characteristics of 68Ga-XT771 will also be assessed.

Interventions

DRUG68Ga-XT771

68Ga-XT771 is injected intravenously with a dose of 4-8 mCi

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

DIAGNOSTIC

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* 1\. signed the informed consent 2. ≥18 years old 3. Patients with glioblastoma or clear cell renal cell carcinoma

Exclusion criteria

* 1\. Known allergy to components of the investigational drug or its analogues 2. suspected to have a certain disease or condition that is not suitable for the study drug 3. Known pregnant or lactating women

Design outcomes

Primary

Measure	Time frame	Description
Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]	7 days following injection	Evaluation of Adverse Events (AE) Using CTCAE

Countries

China

Contacts

Primary ContactRuimin Wang

wrm@yeah.net+8613501151740

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026